Abstract
Alzheimer’s disease (AD) is the most important cause of dementia and a
complex chronic neurodegenerative disease. Many of the currently marketed drugs are
used to treat this disease condition, but a major issue with these drugs is their
neurotoxicity. Alzheimer's treatment with the FDA approval of memantine resolves the
neurotoxicity issue. Memantine acts on glutamate and its receptors in the treatment of
AD. Recent studies show that NMDA receptor-acting drugs are doing well in the
healing of Alzheimer's patients, because of their selectivity on receptor and
neuroprotective activity. The present work is an attempt to collect updated information
about memantine and glutamate antagonists used for the treatment of AD.
Keywords: Alzheimer's Disease, Amyloid Beta Precursor Protein (APP), Central Nervous System, Glutamate, Memantine
Related Journals
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Drug Delivery
Current Bioactive Compounds
Current Drug Safety
Reviews on Recent Clinical Trials
Drug Delivery Letters
Recent Advances in Drug Delivery and Formulation
Recent Advances in Anti-Infective Drug Discovery
Drug Metabolism and Bioanalysis Letters
Applied Drug Research, Clinical Trials and Regulatory Affairs
Related Books
Biotechnology and Drug Development for Targeting Human Diseases
4th International Conference on Drug Discovery and Therapy - 2012
Applied Computer-Aided Drug Design: Models and Methods
Computational Toxicology for Drug Safety and a Sustainable Environment
A Comprehensive Text Book on Self-emulsifying Drug Delivery Systems
Angiogenesis & Therapeutic Targets In Cancer
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development